Spatial Normalization of 18F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
暂无分享,去创建一个
Jens Sörensen | Johan Lilja | Irina Savitcheva | Konstantinos Chiotis | Agneta Nordberg | Antoine Leuzy | I. Savitcheva | A. Nordberg | K. Chiotis | A. Leuzy | J. Lilja | J. Sörensen
[1] R.伦德奎斯特,et al. Methods of spatial normalization of positron emission tomography images , 2012 .
[2] L. Thurfjell,et al. Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.
[3] M. J. D. Powell,et al. An efficient method for finding the minimum of a function of several variables without calculating derivatives , 1964, Comput. J..
[4] Jyrki Lötjönen,et al. Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data , 2013, The Journal of Nuclear Medicine.
[5] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[6] Lennart Thurfjell,et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.
[7] Econor,et al. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS , 2002 .
[8] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[9] B. Dubois,et al. Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study , 2018, Alzheimer's & Dementia.
[10] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[11] W. Klunk. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia , 2011, Neurobiology of Aging.
[12] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[13] C. Rowe,et al. Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias , 2011, The Journal of Nuclear Medicine.
[14] J C Mazziotta,et al. Automated image registration: II. Intersubject validation of linear and nonlinear models. , 1998, Journal of computer assisted tomography.
[15] D. Mankoff,et al. Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation , 2015, American Journal of Neuroradiology.
[16] W. M. van der Flier,et al. Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design , 2017, Alzheimer's & dementia.
[17] Olivier Salvado,et al. MR-Less High Dimensional Spatial Normalization of 11C PiB PET Images on a Population of Elderly, Mild Cognitive Impaired and Alzheimer Disease Patients , 2008, MICCAI.
[18] Robert A. Koeppe,et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.
[19] P. Pasqualetti,et al. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. , 2016, JAMA neurology.
[20] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.